LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Akcijų sąrašas・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.64 -4.65

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.63

Max

1.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.4M -40M
Pardavimai	6.2M 45M
Pelno marža	-90.427
Darbuotojai	485
EBITDA	-6M -38M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+31.58% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-74M 481M
Ankstesnė atidarymo kaina	6.29
Ankstesnė uždarymo kaina	1.64

Naujienos nuotaikos

By Acuity

50%

166 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

1.13 / N/A Palaikymas ir pasipriešinimas

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 23:58; UTC

Uždarbis

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026-05-07 22:57; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026-05-07 23:52; UTC

Uždarbis

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026-05-07 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-07 23:39; UTC

Rinkos pokalbiai

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026-05-07 23:28; UTC

Rinkos pokalbiai

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026-05-07 23:11; UTC

Uždarbis

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026-05-07 23:06; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026-05-07 23:05; UTC

Uždarbis

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026-05-07 23:04; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026-05-07 23:02; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026-05-07 23:00; UTC

Rinkos pokalbiai

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026-05-07 22:42; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026-05-07 22:33; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 22:32; UTC

Uždarbis

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie: 68% of FY Income From International >MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026-05-07 22:29; UTC

Uždarbis

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026-05-07 22:26; UTC

Uždarbis

Macquarie to End Share Buyback Extended in November>MQG.AU

2026-05-07 22:25; UTC

Uždarbis

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

31.58% į viršų

12 mėnesių prognozė

Vidutinis 2.25 USD 31.58%

Aukščiausias 3 USD

Žemiausias 1 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Pacific Biosciences of California Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.13 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

166 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.